Скачать презентацию Xcell Nutri-Sales P O Box 230 Buccleuch 2066 Скачать презентацию Xcell Nutri-Sales P O Box 230 Buccleuch 2066

a990146d3806ac999b32cd1731496cf4.ppt

  • Количество слайдов: 31

Xcell Nutri-Sales P O Box 230, Buccleuch, 2066 Tel: 011 -804 -2565; Fax: 011 Xcell Nutri-Sales P O Box 230, Buccleuch, 2066 Tel: 011 -804 -2565; Fax: 011 -802 -7101 Cell: 083 -453 -9055 Web Site: www. xcellsales. co. za E-mail: [email protected] co. za Contact: Bob Cole CEO

WELCOME TO THE PRESENTATION ON PHYTO BACILLUS WELCOME TO THE PRESENTATION ON PHYTO BACILLUS

INTRODUCTION AND BACKGROUND INTRODUCTION AND BACKGROUND

BACKGROUND • • • DSM Lafti Acidophilus L 10 Bifida Bacteria BACKGROUND • • • DSM Lafti Acidophilus L 10 Bifida Bacteria

SECOND GENERATION PROBIOTIC (Lafti L 10) • Compatibility – Human GI Tract, Therapeutic Efficiency SECOND GENERATION PROBIOTIC (Lafti L 10) • Compatibility – Human GI Tract, Therapeutic Efficiency • Concentration – 1. 5 Billion • Stability – 1 Year • Viability – Stomach Acid & Bile Survival (9)

Survival of LAFTI L 10 in comparison with other strains (in gastrointestinal model) Survival of LAFTI L 10 in comparison with other strains (in gastrointestinal model)

THERAPEUTICS 1 • • Listeria (6, 7 &13) Cancer (8) Gut Disturbances (10, 11 THERAPEUTICS 1 • • Listeria (6, 7 &13) Cancer (8) Gut Disturbances (10, 11 &12) Antihypertensive Peptides Inhibits Range Of Pathogenic Bacteria Produces Lactose Good Adhesion To Intestinal Mucus Promotes Health & Wellbeing

Inhibition of Listeria in vitro Mahoney et al. (2003) International Journal of Food Microbiology Inhibition of Listeria in vitro Mahoney et al. (2003) International Journal of Food Microbiology (in press) 84: 255 -261

LAFTI® reduces incidence of cancer Control LAFTITML 10 GG Incidence of tumour formation (%) LAFTI® reduces incidence of cancer Control LAFTITML 10 GG Incidence of tumour formation (%) 40 15 20 Large intestinal tumours (no. ) 10 31 4 Tumour mass index (log 10) 1. 7 0. 12 1. 9 statistically different from the control at 5% level (Chi test); 2 statistically different from all other treatments (P<0. 05) 1 Mc. Intosh et al. (1999) Nutrition and Cancer 35: 153 -159

Effect of LAFTI® L 10 on gut disturbances (UNSW) • Placebo controlled, randomized, cross-over Effect of LAFTI® L 10 on gut disturbances (UNSW) • Placebo controlled, randomized, cross-over study • Subjects (n = 60) treated with LAFTI® L 10, Lactobacillus sp. and placebo for 2 weeks Two weeks wash out between treatments Questionnaires completed at the end of each treatment week

How treatment with LAFTI® was perceived Do you think that the capsules have a How treatment with LAFTI® was perceived Do you think that the capsules have a beneficial effect? * Welin et al, UNSW, evaluation completed Q 42003 * Significantly different from the placebo (P < 0. 05)

LAFTI® L 10 reduces gastrointestinal disturbances Have you experienced any of the following gut LAFTI® L 10 reduces gastrointestinal disturbances Have you experienced any of the following gut disturbances while taking the capsules? (circle the number that best describes the severity of the condition: 1 = low, 10 = severe). Welin et al, UNSW, evaluation completed Q 42003 * Significantly different from the placebo (P < 0. 03)

Study in mice – conclusions Conclusion • LAFTI L 10 clears yeast (Candida) infection Study in mice – conclusions Conclusion • LAFTI L 10 clears yeast (Candida) infection rapidly • LAFTI L 10 restores low levels of IFN- Ø Rapid clearance of Candida correlates with the increase of IFN- LAFTI L 10 may be used in restoration of a suppressed immune system and help with protection against Candida infection

STIDY IN HUMANS - conclusions Conclusions • Lafti L 10 restores low levels of STIDY IN HUMANS - conclusions Conclusions • Lafti L 10 restores low levels of IFN-y • There are strong indications that LAFTI L 10 reduces EBV infection (further studies are needed to confirm reduction of EBV infection by LAFTI L 10) LAFTI L 10 may be used in restoration of a suppressed immune system. As a result LAFTI 10 may help in the protection against EBV infection and fatigue related to this infection.

Phyto Bacillus – Candida/CD 4/Weight • GI Tract Compatibility • Significant Reduction In Severity Phyto Bacillus – Candida/CD 4/Weight • GI Tract Compatibility • Significant Reduction In Severity Of Candida • Improved CD 4 Count • Improvement In Weight • More detailed research is needed

 Conclusions • Fatigued athletes have significantly lower IFN-g levels than healthy athletes • Conclusions • Fatigued athletes have significantly lower IFN-g levels than healthy athletes • Intake of LAFTI L 10 increases INF- levels • Intake of LAFTI L 10 has a restorative effect on IFN-g levels in fatigued athletes Ø This pilot study suggest that LAFTI L 10 may be useful in restoration of a suppressed immune system.

Important properties of LAFTI • Are perceived as having a beneficial effect on general Important properties of LAFTI • Are perceived as having a beneficial effect on general health (L 10) • Alleviates symptoms of a wide range of gut disturbances (L 10) • Reduce survival of Listeria in the GI tract of animals L 10 • Inhibit range of pathogenic bacteria in vitro (L 10, L 26, B 94) • Protect against small and large intestinal cancers in animals (L 10) • Produce antihypertensive peptides (L 10, L 26, B 94) • Produce lactose (L 10, L 26, B 94) • Good survival in capsules (L 10, L 26, B 94) • Contribute to increased food safety (L 10, L 26, B 94)

PREBIOTIC Fructo Oligosaccharide (FOS) • Nutritional Base For Bacillus • Fibre Base Promotes Colonization PREBIOTIC Fructo Oligosaccharide (FOS) • Nutritional Base For Bacillus • Fibre Base Promotes Colonization • p. H Balance Promotes Colonization • NOTE • Probiotics should be combined with broad spectrum dietary fiber for optimum therapeutic efficiency

PHYTO BACILLUS • Developed In South Africa In Consultation With DSM • Clinical Trials PHYTO BACILLUS • Developed In South Africa In Consultation With DSM • Clinical Trials – University Of The Orange Free State – In Progress • Phyto Bacillus – Advanced Technology, Therapeutic Efficiency - Integrity

SYNBIOTICS SYNBIOTICS

SYNBIOTICS - 1 • • • GI TRACT Indigestion, Heart Burn Reflux, Diarrhea, Constipation SYNBIOTICS - 1 • • • GI TRACT Indigestion, Heart Burn Reflux, Diarrhea, Constipation Irritable Bowel & Leaky Gut Syndromes Ulcerous Colitis & Ulcers, Crohn’s Disease • Gastrointestinal Infections • Food Allergies

SYNBIOTICS 2 • IMMUNE SYSTEM • Reestablishes Bacterial Efficiency – Antibiotics, Chemo & Radiation SYNBIOTICS 2 • IMMUNE SYSTEM • Reestablishes Bacterial Efficiency – Antibiotics, Chemo & Radiation Therapies, Anti-Inflammatories, ARV’s • Increases Immunoglobulin A • Increases Non Specific Antigens (Phagocytic Activity) • Liver Dysfunction & Liver Related Brain Dysfunction

SYNBIOTICS 3 • CANCER • Inhibits Growth Rate Of Tumors • Inhibits Bacteria That SYNBIOTICS 3 • CANCER • Inhibits Growth Rate Of Tumors • Inhibits Bacteria That Convert Matter Into Carcinogens • Binds And Inactivates Some Carcinogens • Builds Non Specific Antigens – (Phagocytic Activity) • Increases Immunoglobulin A Count

SYNBIOTICS 4 • HEART & CARDIOVASCULAR • Lowers Triglycerides, LDL Cholesterol & Total Cholesterol SYNBIOTICS 4 • HEART & CARDIOVASCULAR • Lowers Triglycerides, LDL Cholesterol & Total Cholesterol • Reduces Serum Fat And Blood Sugars • Hypertension • Diabetes

USAGE • Nutrition Not Medication • Treating Causes Not Disease Symptoms • Most Synbiotic USAGE • Nutrition Not Medication • Treating Causes Not Disease Symptoms • Most Synbiotic Applications Need Long Term Therapeutic Usage Of At Least Thirty Days i. e. One Jar, To Address Dysfunction • Safe For Children (1 Year & Older), Pregnant and Lactating Mothers • Safe In Higher Usage Applications, Under Supervision Of Physician/Doctor/Health Practitioner

USAGE Cont. • Two Capsules Per Day • Optimum Therapeutic Benefit – Half An USAGE Cont. • Two Capsules Per Day • Optimum Therapeutic Benefit – Half An Hour Before Meals – Otherwise With Meals • Safe For Long Term Usage – More Than a Month • Store At Below 25%C • Store Under In Refrigerator After Opening Pack

COMMERCIAL COMMERCIAL

Retail Pharmacy Prices • COST • 1 to 9 Units - R 109. 76 Retail Pharmacy Prices • COST • 1 to 9 Units - R 109. 76 ea • * Bonus Offer • Buy 10, Get 1 Free • Cost R 1 097. 60 • SELLING • 1 to 9 Units - R 164. 63 ea • Mark Up On Cost = 50% • * Bonus Offer • Buy 10, get 1 Free • Turnover = R 1 810. 93 • Mark Up On Cost = 65% • * Per 10 Capsules Dispensed @ R 29. 90 • Mark Up On Cost = 80%

ORDERS • PRIMARY NATIONAL DISTRIBUTOR • Medi-Focus – 011 -201 -6000 • Transfarm – ORDERS • PRIMARY NATIONAL DISTRIBUTOR • Medi-Focus – 011 -201 -6000 • Transfarm – UPD • Other Wholesalers

REGISTRATIONS • • • MCC – Submitted – Schedule S 0 NAPPI Code – REGISTRATIONS • • • MCC – Submitted – Schedule S 0 NAPPI Code – 704859 -001 Barcode - All Stock Wholesalers Listings – Under Negotiation Store At Below 25%C Store In Refrigerator Once Pack Is Opened

THANK YOU FOR GOING THROUGH THIS PRESENTATION WITH US WE LOOK FORWARD TO DOING THANK YOU FOR GOING THROUGH THIS PRESENTATION WITH US WE LOOK FORWARD TO DOING BUSINESS WITH YOU